Health Minister Yasuhisa Shiozaki said on August 1 that it is “very regrettable” that Bayer Yakuhin failed to report adverse drug reactions (ADRs) to regulatory authorities as it does not fulfill its obligation under the Pharmaceuticals and Medical Devices Law.“The…
To read the full story
Related Article
- Bayer Yakuhin Finds 85 Further Cases of Unreported ADRs
August 2, 2017
REGULATORY
- Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





